Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

This publication has 22 references indexed in Scilit:

• Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study
  Cancer Chemotherapy and Pharmacology, 2003
• Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial
  Journal of Clinical Oncology, 2003
• Phase II Study of Concurrent Administration of Doxorubicin and Docetaxel as First-Line Chemotherapy for Metastatic Breast Cancer
  Oncology, 2003
• Accelerated versus standard cyclophosphamide, epirubicin and5-fluorouracil or cyclophosphamide, methotrexate and5-fluorouracil: a randomized phase III trial in locally advanced breast cancer
  Annals of Oncology, 2003
• Randomized, Controlled, Multicenter Phase III Trial of Standard-Dose Fluorouracil-Epirubicin- Cyclophosphamide (FEC), Compared with Time-Intensive FEC (FEC-G) and Mitoxantrone-Methotrexate-Mitomycin C (MMM-G) in Metastatic Breast Carcinoma
  Journal of Chemotherapy, 2003
• Chemotherapy for metastatic breast cancer–report of a European expert panel
  The Lancet Oncology, 2002
• Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure
  British Journal of Cancer, 2002
• Phase II study of docetaxel and epirubicin in Chinese patients with metastatic breast cancer
  Anti-Cancer Drugs, 2002
• Combination chemotherapy for metastatic breast cancer
  Expert Review of Anticancer Therapy, 2002
• Docetaxel with epirubicin as first line chemotherapy in metastatic breast cancer (MBC). Final results of a Phase II study
  European Journal Of Cancer, 2002